Professionals from pharma, biotech, and device industries focus on manufacturing, bioprocessing, development technologies; exhibition, technical sessions, networking on efficiency, quality, compliance across product lifecycle.
Canadian biotech company Providence Therapeutics has announced its support for the PaedNEO-VAX clinical study — a program testing personalized mRNA vaccines for children and teens with the most severe, treatment-resistant brain tumors. The project is set to launch in Australia in March 2026, and organizers say patient enrollment will run through a network of 7–8 pediatric hospitals and clinics across several states.
Language models are widely capable of answering health-related questions — a topic that the media have covered extensively. These are truly remarkable advancements. However, the process of implementing them into real life rarely draws the same attention; it is accompanied by tedious paperwork and annoying safety issues.
Pfizer has released mid-stage (Phase 2b) VESPER-3 results: its experimental drug PF’3944 (previously known as MET-097i and brought into Pfizer via the Metsera deal) helped people with obesity or overweight lose up to 12.3% of body weight (placebo-adjusted) by week 28. The headline feature is the dosing schedule: patients started with weekly injections during dose escalation, then switched to a once-monthly maintenance shot. Pfizer says there was no clear weight-loss “plateau” by week 28, and the trial continues through week 64.
Modern medical practice is virtually unthinkable without numerous wearable electronic devices. Miniature flexible devices that continuously monitor blood glucose levels, blood pressure, pulse, or other vital parameters have become an integral part of daily life and an indispensable element of diagnostics and treatment.
Medtronic announced on February 3, 2026, its intent to exercise its option to acquire CathWorks, an Israeli medical device company specializing in AI-driven coronary artery disease diagnostics, in a deal valued at up to $585 million plus potential undisclosed earn-out payments. The acquisition, pending U.S. Federal Trade Commission clearance, is expected to close by the end of Medtronic’s fiscal year 2026.
A few weeks ago, the world’s largest annual consumer electronics exhibition — the Consumer Electronics Show (CES) 2026 — came to an end. CES 2026 delivered a parade of ambitious consumer tech: AI companions, advanced driver assistance, home humanoids, and smarter devices for everyday life. It’s impressive, yet at times the demos feel like a polished version of ideas we’ve already seen in speculative fiction, with just enough “Black Mirror” energy to make you pause.
Health tech was one of the most visible themes at CES 2026 — from smart diagnostics to wearable neurostimulation and at-home monitoring. These tools promise earlier insights and more personalized care, yet conspicuously resemblant of Black Mirror episodes: they listen, track, and interpret our daily lives in ways that conflate health monitoring with constant surveillance.
The Bill & Melinda Gates Foundation and OpenAI have announced a joint $50 million initiative aimed at using artificial intelligence to support and improve healthcare systems across African countries. The project, called Horizon1000, was unveiled at the World Economic Forum in Davos and is set to deploy AI tools in primary healthcare, starting in Rwanda.
Bristol Myers Squibb and Microsoft announced on Tuesday a partnership aimed at accelerating the early detection of lung cancer using artificial intelligence across the U.S. healthcare system. The collaboration will be implemented through Microsoft’s Precision Imaging Network, a platform that analyzes X-ray and CT scans using FDA-cleared AI algorithms.